TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, ...
Shares of TransCode Therapeutics, Inc.RNAZ fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares ...
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a ...
TransCode's TTX delivery platform is currently being evaluated in clinical trials, underscoring the translational feasibility of this immunotherapy approach. Molecular Imaging and Biology is a ...
No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results Several patients in the first and second cohort remain on ...
Transcode Therapeutics (NASDAQ: RNAZ) is up 1,969 % in premarket trading today. But the volume of shares traded is all of 727 according to NASDAQ itself. This is not normally how we think of stock ...
First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded ...
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that ...
BOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, in collaboration ...
TransCode Therapeutics Inc (NASDAQ:RNAZ) shares are trading higher Thursday after the company announced it received written authorization from the FDA to proceed with its First-in-Human Phase 0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results